Diagnosis and Treatment of Neuroendocrine Tumors
About the Lecture
Joseph Pisegna, MD, Professor of Medicine and Human Genetics, researcher and gastroenterologist, J. Randolph Hecht, MD, Professor of Clinical Medicine researcher, oncologist and gastroenterologist, Ken Herrmann, MD, Associate Professor, researcher and nuclear medicine physician,Timothy R. Donahue, MD, PhD, Associate Professor of Surgery and Molecular & Medical Pharmacology researcher and surgeon discuss neuroendocrine tumors (NETS) which include both carcinoid tumors and pancreatic islet cell tumors. The latest research and clinical interventions including imaging and diagnosis, staging and the role of hormonal, chemotherapy and targeted treatment approaches. The interdisciplinary discussion illustrates the importance of an evidence based driven integrated interdisciplinary team approach for best outcomes for patients with NETS.
Joseph Pisegna, MD is a Professor of Medicine Professor of Medicine and Human Genetics at UCLA and Chief of the Division of Gastroenterology and Hepatology at the VA Greater Los Angeles Healthcare System. Dr. Pisegna is interested in the molecular pharmacology of hormones and receptors in the gastrointestinal tract, especially the diagnosis and management of islet cell tumors of the pancreas. His research and clinical interests derive from research in the biochemistry and physiology of neuroendocrine tumors. His addition to the faculty of the UCLA Center for Pancreatic Diseases provides unsurpassed expertise in the diagnosis and medical management of pancreatic endocrine tumors.
Timothy R. Donahue, MD is an Associate Professor of Surgery and Molecular & Medical Pharmacology at the David Geffen School of Medicine at UCLA. He is the Director of the Pancreatic Translational Program at the UCLA Institute for Molecular Medicine. His clinical practice is focused on pancreatic surgery, and his research program examines the molecular genetics of pancreatic cancer.
J. Randolph Hecht, MD is a Professor of Clinical Medicine in the David Geffen School of Medicine at UCLA School of Medicine. He holds the Carol and Saul Rosenzweig Chair for Cancer Therapies Development and is the Director of the UCLA Gastrointestinal Oncology Program. Dr. Hecht is an internationally known clinical and translational researcher in the field of gastrointestinal cancers. He has published widely on the molecular biology, early detection, and treatment of gastrointestinal malignancies.
Ken Herrmann, MD, is an Associate Professor in the Department of Molecular and Medical Pharmacology at the David Geffen School of Medicine at UCLA. He graduated from Charité in Berlin (Germany) in 2004 and was trained in nuclear medicine in Munich. He has been at UCLA since 2011. In addition, he serves as Chair of Nuclear Medicine at Universitätsklinikum Essen, Germany. His research focuses on radionuclide theranostics especially in neuroendocrine tumors.
7:00 p.m. – 9:00 p.m.
6:45 – 7:00: Arrival & Refreshments
7:00 – 7:15: Anne Coscarelli, Ph.D, Introduction to Center
7:15 – 7:20: Anne Coscarelli, Ph.D., Speaker Introduction
7:20 – 8:55: Speaker Presentation, Q&A
8:55 – 9:00: Closing
Ronald Reagan UCLA Medical Center (RRMC) Auditorium,
B Level, Room B130, 757 Westwood Plaza, Los Angeles, CA 90095
Attendance is Free.
Available at the Medical Plaza or Ronald Reagan Medical Center lots for $12.00